AI Technology Group Enhances Presence with Acquisition of AVM Biotechnology
AI Technology Group Inc. (OTCID: AIPG) has embarked on a pivotal journey by announcing its definitive agreement to acquire AVM Biotechnology Inc. This exciting development marks a significant turning point in the company’s trajectory, as they seek to merge their operations effectively to accelerate innovative cancer therapies.
Acquisition Overview
As part of the acquisition, a newly formed subsidiary of AI Technology Group will undergo a merger with AVM, transforming it into a wholly owned subsidiary of AI Technology Group upon closing of the agreement. This merger is contingent upon customary closing conditions as outlined in their official filings, and it is designed to strengthen both entities' positions in the biotechnology sector. This strategic move reflects AI Technology Group's commitment to enhancing its market capabilities and aligning its corporate identity with the visionary goals of AVM.
A New Era for Cancer Treatment
AVM Biotechnology is at the forefront of developing innovative treatments, particularly with its groundbreaking product, AVM0703. This fully developed small-molecule drug is aimed at tackling a myriad of cancer forms through an advanced one-hour outpatient infusion procedure. The drug is designed to reactivate the body’s Reserve Immune System, effectively harnessing specific T lymphocytes and Natural Killer T cells aimed at eradicating cancerous and abnormal cells.
AVM0703: A Game-Changer in Oncology
AVM0703 represents a remarkable advancement in the field of oncology. With its unique formulation, the treatment boasts a two-year shelf life and stability at room temperature, making it accessible beyond traditional hospital settings. Tailored for both blood cancers and various solid tumors, this promising drug has concluded several phases of clinical trials with no significant safety signals reported, even after extensive treatments.
This innovative drug isn't just limited to oncology; preclinical and clinical research suggests that AVM0703 could also play a vital role in treating autoimmune diseases, including rheumatoid arthritis and diabetes, as well as certain infectious diseases. Its comprehensive approach opens avenues for broader therapeutic applications, positioning AVM at the cutting edge of medical research and treatment methodology.
Clinical Trials and Real-World Data
As of now, over ninety patients have benefitted from AVM0703 through various clinical trials and compassionate use programs. The results from these efforts have been promising, with no cumulative toxicity observed despite multiple rounds of dosing. These findings not only underscore the drug's safety profile but also enhance the predictive power of clinical outcomes based on real-world applications, a crucial aspect in evaluating new therapies.
Leadership and Vision
Dr. Theresa Deisher, an esteemed expert in the fields of stem-cell research and immunology, leads AVM’s ambitious initiatives. With over three decades of experience in drug discovery and development, Dr. Deisher’s leadership significantly supports AVM's innovative efforts. She is recognized for her extensive portfolio of patents and her academic foundations laid at Stanford University, further solidifying AVM's position in the biotechnology landscape.
Financing the Future
To fuel the clinical development and operations linked to this acquisition, AI Technology Group is undertaking a private financing initiative, aiming to raise at least $14 million. This fundraising effort, priced at $2.50 per share, is geared towards balancing shareholders' interests while strategically advancing the company’s development goals.
About AI Technology Group Inc.
AI Technology Group, a Nevada-based corporation, is poised for growth and innovation in the biotechnology sector. With the anticipated effectiveness of its Form 10, the company will adhere to ongoing SEC reporting requirements, ensuring transparency and accountability as it transitions into this new phase of operations.
Frequently Asked Questions
What is the main goal of AI Technology Group’s acquisition?
The primary goal is to enhance the company’s capabilities in cancer treatment by merging operations with AVM Biotechnology and integrating innovative therapies.
Who leads AVM Biotechnology?
AVM Biotechnology is led by Dr. Theresa Deisher, an experienced stem-cell and immunology expert with significant accomplishments in drug development.
What is AVM0703?
AVM0703 is a small-molecule drug designed to activate the body’s immune system to fight cancer, with potential applications in autoimmune and infectious diseases.
How is the acquisition being financed?
AI Technology Group is seeking to raise at least $14 million through a private financing initiative to support AVM’s clinical development and operations.
What does this acquisition mean for the future of AI Technology Group?
This acquisition signals a strategic shift towards expanding their biotechnology focus, improving operational capacity, and potentially changing their corporate identity.
